Boston Scientific has announced that Isabel Newton has been named chief medical officer of the company’s interventional oncology (IO) and embolization business.
The company have stated that Newton joining Boston Scientific will support deeper engagement across the oncology landscape and strengthen our leadership in a rapidly evolving field.
Newton is a board-certified diagnostic and interventional radiologist with deep clinical, academic, leadership and research experience in oncology. She previously served as chief of interventional radiology (IR) at the Veterans Affairs San Diego Health Care System in San Diego, USA and as a professor at University of California, San Diego Health, where she also held leadership roles in faculty development and wellness.
Her research has focused on liver cancer, including cancer stem cells, cryoablation and immuno-oncology. Newton earned her doctor of medicine (MD) from Wake Forest School of Medicine, where she also completed a doctor of philosophy (PhD) in neurobiology and anatomy. She is the co-founder and chair of the Interventional Initiative, a nonprofit organisation that promotes minimally invasive, image-guided care.
Boston Scientific’s portfolio of cancer and embolization products includes the EMBOLD detachable coil system, which recently received CE Mark in Europe; hepatic artery infusion therapy, which it obtained through last year’s acquisition of Intera Oncology; and TheraSphere Y-90 glass microspheres, which are used to treat primary liver cancer.
